Symlin Dose Titration Mitigates Hypoglycemia, Nausea, Amylin Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amylin’s recent Symlin NDA amendment shows that a dose titration regimen reduces the risks of nausea and hypoglycemia in type 1 and 2 diabetes patients, the firm reported June 15.